newsfilter
← Latest News
PR Newswire·

Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Sept. 6, 2023 /PRNewswire/ -- Gracell Biotechnologies Inc. ((", Gracell", or the ", Company", , NASDAQ:GRCL), a global clinical-stage biopharmaceutical